Psychiatry Research
Volume 169, Issue 2 , Pages 118-123 , 30 September 2009

Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: A randomized, open-labeled trial

  • Eun-Ho Kang

      Affiliations

    • Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
    • ,
  • In-Soo Lee

      Affiliations

    • Department of Psychiatry, Semin Mental Hospital, Yeoju, South Korea
    • ,
  • Sang-Keun Chung

      Affiliations

    • Department of Psychiatry, Chonbuk National University Medical School, Jeonju, South Korea
    • ,
  • Sang-Yeol Lee

      Affiliations

    • Department of Psychiatry, School of Medicine, Wonkwang University, Iksan, South Korea
    • ,
  • Eui-Jung Kim

      Affiliations

    • Department of Psychiatry, College of Medicine, Ewha Womans University, Seoul, South Korea
    • ,
  • Jin-Pyo Hong

      Affiliations

    • Department of Psychiatry, College of Medicine, Asan Medical Center, Ulsan University, Seoul, South Korea
    • ,
  • Kang-Seob Oh

      Affiliations

    • Department of Psychiatry, Sungkyunkwan University School of Medicine, Kangbuk Samsung Hospital, Seoul, South Korea
    • ,
  • Jong-Min Woo

      Affiliations

    • Department of Neuropsychiatry and Stress Research Institute, Seoul Paik Hospital, Inje University, School of Medicine, Seoul, South Korea
    • ,
  • Seonwoo Kim

      Affiliations

    • Biostatistics Unit of Samsung Biomedical Research Institute, Seoul, South Korea
    • ,
  • Joo-Eon Park

      Affiliations

    • Department of Psychiatry, Keyo Hospital, Euiwang, South Korea
    • ,
  • Bum-Hee Yu

      Affiliations

    • Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
    • Corresponding Author InformationCorresponding author. Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine, Ilwon-Dong 50, Gangnam-Gu, Seoul, South Korea 135-710. Tel.: +82 2 3410 3583; fax: +82 2 3410 6957.

Received 10 December 2007 ,Revised 27 May 2008 ,Accepted 12 June 2008.

References 

  1. Bomholt SF, Mikkelsen JD, Blackburn-Munro G. Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. Neuropharmacology. 2005;48:252–263
  2. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Research. 1989;28:193–213
  3. Delgado PL. Common pathways of depression and pain. Journal of Clinical Psychiatry 65 Suppl. 2004;12:16–19
  4. Derogatis LR. Symptom Checklist-90-Revised (SCL-90-R) Manual I. Baltimore: Clinical Psychometric Research Unit, Johns Hopkins University; 1977;
  5. Entsuah R. Venlafaxine vs SSRIs: comparison of somatic symptom resolution. World Journal of Biological Psychiatry. 2004;5:11
  6. Fava M. Somatic symptoms, depression, and antidepressant treatment. Journal of Clinical Psychiatry. 2002;63:305–307
  7. Fava M. The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression. Journal of Clinical Psychiatry. 2003;64(Suppl 13):26–29
  8. Fava M. Depression with physical symptoms: treating to remission. Journal of Clinical Psychiatry. 2003;64(Suppl 7):24–28
  9. Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. Journal of Affective Disorder. 1998;51:267–285
  10. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders. New York: Biometrics Research, New York State Psychiatric Institute; 1996;
  11. Fishbain D. Evidence-based data on pain relief with antidepressants. Annals of Medicine. 2000;32:305–316
  12. Freynhagen R, Muth-Selbach U, Lipfert P, Stevens MF, Zacharowski K, Tolle TR, et al. The effect of mirtazapine in patients with chronic pain and concomitant depression. Current Medical Research Opinion. 2006;22:257–264
  13. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology. 1959;32:50–55
  14. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry. 1960;23:56–62
  15. Jann MW, Slade JH. Antidepressant agents for the treatment of chronic pain and depression. Pharmacotherapy. 2007;27:1571–1587
  16. Katon W, Kleinman A, Rosen G. Depression and somatization: a review. Part I. American Journal of Medicine. 1982;72:127–135
  17. Keller MB, Berndt ER. Depression treatment: a lifelong commitment?. Psychopharmacology Bulletin. 2002;36(Suppl 2):133–141
  18. Kroenke K, Price RK. Symptoms in the community. Prevalence, classification, and psychiatric comorbidity. Archives of Internal Medicine. 1993;153:2474–2480
  19. Kroenke K, Spitzer RL, Williams JBW, Linzer M, Hahn SR, deGruy FV, et al. Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment. Archives of Family Medicine. 1994;3:774–779
  20. Kroenke K, Spitzer RL, Williams JBW. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosomatic Medicine. 2002;64:258–266
  21. Kroenke K, Messina N, Benattia I, Graepel J, Musgnung J. Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder. Journal of Clinical Psychiatry. 2006;67:72–80
  22. O'Malley PG, Jackson JL, Santoro J, Tomkins G, Balden E, Kroenke K. Antidepressant therapy for unexplained symptoms and symptom syndromes. Journal of Family Practice. 1999;48:980–990
  23. Papakostas GI, Petersen T, Denninger J, Sonawalla SB, Mahal Y, Alpert JE, et al. Somatic symptoms in treatment-resistant depression. Psychiatry Research. 2003;118:39–45
  24. Ruoff GE. Depression in the patient with chronic pain. Journal of Family Practice. 1996;43:S25–S33discussion S34
  25. Samborski W, Lezanska-Szpera M, Rybakowski JK. Open trial of mirtazapine in patients with fibromyalgia. Pharmacopsychiatry. 2004;37:168–170
  26. Sayar K, Aksu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. Annals of Pharmacotherapy. 2003;37:1561–1565
  27. Schreiber S, Bleich A, Pick CG. Venlafaxine and mirtazapine: different mechanisms of antidepressant action, common opioid-mediated antinociceptive effects—a possible opioid involvement in severe depression?. Journal of Molecular Neuroscience. 2002;18:143–149
  28. Seemüller F, Riedel M, Wickelmaier F, Adli M, Mundt C, Marneros A, et al. Atypical symptoms in hospitalised patients with major depressive episode: frequency, clinical characteristics, and internal validity. Journal of Affective Disorders. 2008;108:271–278
  29. Simon GE, VonKorff M, Piccinelli M, Fullerton C, Ormel J. An international study of the relation between somatic symptoms and depression. New England Journal of Medicine. 1999;341:1329–1335
  30. Smith AJ. The analgesic effects of selective serotonin reuptake inhibitors. Journal of Psychopharmacology. 1998;12:407–413
  31. Stahl SM. The psychopharmacology of painful physical symptoms in depression. Journal of Clinical Psychiatry. 2002;63:382–383
  32. Wellington K, Perry CM. Venlafaxine extended-release: a review of its use in the management of major depression. CNS Drugs. 2001;15:643–669
  33. Wessely S, Hindmarch I. Taking the pain out of depression: dual action antidepressants in the relief of pain in depression, fibromyalgia and other chronic pain syndromes. Human Psychopharmacology. 2004;19(Suppl 1):S1–2

☆ Conflict of Interests: This study was supported by a grant from Organon Korea.

PII: S0165-1781(08)00189-3

doi: 10.1016/j.psychres.2008.06.021

Psychiatry Research
Volume 169, Issue 2 , Pages 118-123 , 30 September 2009

Article Tools

* Image Usage & Resolution